SPELMYZE Trademark

Trademark Overview


On Friday, October 11, 2019, a trademark application was filed for SPELMYZE with the United States Patent and Trademark Office. The USPTO has given the SPELMYZE trademark a serial number of 88651260. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 22, 2023. This trademark is owned by Eli Lilly and Company. The SPELMYZE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
spelmyze

General Information


Serial Number88651260
Word MarkSPELMYZE
Filing DateFriday, October 11, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 22, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 25, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 17, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, May 22, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 22, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, September 23, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 22, 2022SOU EXTENSION 5 GRANTED
Monday, September 19, 2022SOU EXTENSION 5 FILED
Monday, September 19, 2022TEAS EXTENSION RECEIVED
Thursday, March 17, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 16, 2022SOU EXTENSION 4 GRANTED
Monday, March 14, 2022SOU EXTENSION 4 FILED
Monday, March 14, 2022TEAS EXTENSION RECEIVED
Saturday, September 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 16, 2021SOU EXTENSION 3 GRANTED
Thursday, September 16, 2021SOU EXTENSION 3 FILED
Thursday, September 16, 2021TEAS EXTENSION RECEIVED
Wednesday, March 24, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 22, 2021SOU EXTENSION 2 GRANTED
Monday, March 22, 2021SOU EXTENSION 2 FILED
Monday, March 22, 2021TEAS EXTENSION RECEIVED
Friday, September 25, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 24, 2020SOU EXTENSION 1 GRANTED
Wednesday, September 16, 2020SOU EXTENSION 1 FILED
Thursday, September 24, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 16, 2020TEAS EXTENSION RECEIVED
Tuesday, April 21, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 25, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 25, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 5, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 17, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 10, 2020ASSIGNED TO EXAMINER
Thursday, October 17, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 15, 2019NEW APPLICATION ENTERED